No Data
No Data
No Data
No Data
No Data
Shanghai Pharmaceutical (02607) plans to apply for the issuance of various short-term debt financing products and medium- to long-term debt financing products
Shanghai Pharmaceutical (02607) issued an announcement. The company plans to apply for a distribution balance of not more than RMB 15 billion worth of all types...
Zhitong FinanceApr 26 05:14 ET
Shanghai Pharmaceutical (02607.HK) net profit of 1,542 billion yuan in the first quarter increased 1.62% year-on-year
Gelonghui, April 26 | Shanghai Pharmaceutical (02607.HK) announced that in the first quarter of 2024, during the reporting period, the company's main business grew steadily, achieving operating revenue of 70.153 billion yuan (currency is RMB, same below), an increase of 5.93% over the previous year. Among them, the pharmaceutical industry achieved sales revenue of 6.944 billion yuan, a year-on-year decrease of 10.98%; the pharmaceutical business achieved sales revenue of 63.209 billion yuan, an increase of 8.19% over the previous year. During the reporting period, the company achieved net profit attributable to shareholders of listed companies of 1,542 billion yuan, an increase of 1.62% over the previous year. Among them, the industrial business contributed profit
Gelonghui FinanceApr 26 04:39 ET
上海醫藥:2024年第一季度報告
Futu NewsApr 26 04:32 ET · Announcements
上海醫藥:2023 年年報
Futu NewsApr 26 04:30 ET · Announcements
Hong Kong Stock Concept Tracking | The 2024 trend of mergers and acquisitions of pharmaceutical distribution companies is expected to further accelerate leading state-owned enterprises to attract attention (with concept stocks)
The trend of mergers and acquisitions of domestic pharmaceutical distribution companies is expected to accelerate further, and the concentration of leaders may further increase
Zhitong FinanceApr 25 01:46 ET
SDIC Securities: The industry is heavily state-owned capital, and the trend of mergers and acquisitions of pharmaceutical distribution companies is expected to accelerate further in 24 years
The new round of state-owned enterprise reform also emphasizes specialized integration in the medical and health sector. The pharmaceutical distribution industry is heavily state-owned and driven by superposition policies. At the time point of 2024, the trend of mergers and acquisitions of domestic pharmaceutical distribution companies is expected to further accelerate.
Zhitong FinanceApr 24 23:22 ET
No Data
No Data